Temazepam is a benzodiazepine sold under the brand name Restoril and prescribed for short term treatment of insomnia. It is classified as a Schedule IV controlled substance by the Drug Enforcement Administration because, like other benzodiazepines, it carries a documented risk of misuse, dependence, and withdrawal. According to the current prescribing label on file with the National Library of Medicine, temazepam is intended for short term use, generally limited to seven to ten days, and carries a boxed warning about the dangers of combining it with opioids or other central nervous system depressants. The StatPearls chapter on temazepam describes the same Schedule IV classification and notes that the drug is handled through the liver rather than needing active renal clearance, which is relevant to how long it and its minor metabolites remain detectable.
Because temazepam is a true benzodiazepine, not a look alike compound that merely resembles one, a person taking it as prescribed or using it without a prescription will generally test positive on a standard benzodiazepine (BZO) immunoassay screen. This article explains how that screen works, why some benzodiazepines are picked up more reliably than others, what a laboratory confirmation step adds, and why a documented prescription still needs to go through medical review officer (MRO) channels rather than being waved off as a false positive.
What the BZO Panel Is Actually Measuring
Rapid drug test cups, dip cards, and cassettes that include a BZO panel use an immunoassay. An immunoassay relies on antibodies that bind to a target molecule, or to molecules that share a similar chemical shape. The StatPearls chapter on toxicology screening describes this class of point of care and laboratory screening tests as fast and inexpensive, but inherently a presumptive step rather than a definitive identification, because the antibody can react to more than one structurally related compound.
Most commercial BZO immunoassays were originally built around antibodies raised against oxazepam or nordiazepam, two compounds that sit downstream in the metabolic pathway shared by several older benzodiazepines, including diazepam, chlordiazepoxide, and temazepam itself. Temazepam is a minor metabolic product of diazepam and shares much of that same chemical backbone, which is part of why it reacts dependably with this class of antibody at the cutoff concentrations manufacturers typically validate against. In practical terms, a person taking temazepam as directed, or someone who has taken diazepam, will usually screen positive on a standard BZO cup or dip card.
Why Some Benzodiazepines Are Detected Less Reliably
Not every benzodiazepine reacts the same way with the same antibody. Clonazepam, lorazepam, and alprazolam are structurally different enough, and their urinary metabolites are conjugated differently, that some screening immunoassays show reduced sensitivity to them at the manufacturer's standard cutoff. The StatPearls chapter on benzodiazepine toxicity notes that standard urine immunoassay panels can miss certain benzodiazepines or their metabolites, which is one reason a negative screen in a person who reports taking a prescribed benzodiazepine is not automatically treated as proof of nonuse.
Temazepam does not have that same reputation. Its chemistry overlaps closely enough with the diazepam and oxazepam family that cross reactivity on standard panels is well established rather than marginal. That does not mean every cup or card detects it at every concentration. Cutoffs and antibody formulations vary by manufacturer, and a specimen with a temazepam concentration below a given cutoff will read negative even though the drug is present. This is a limitation of screening generally, not evidence that the drug is somehow invisible to testing.
Screening Versus Confirmation
A positive immunoassay result is a screening result, not a final answer. The accepted next step, described in the StatPearls chapter on drug testing, is confirmation by gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC/MS or LC/MS/MS). These confirmation methods separate and identify individual molecules rather than relying on antibody cross reactivity, so a laboratory report can specify that the compound present is temazepam, as distinct from diazepam, oxazepam, or another benzodiazepine in the same family. Employers, clinics, and treatment programs that need a defensible result should always pair a screening positive with confirmation before any adverse action or clinical decision is made.
| Benzodiazepine | Typical immunoassay detectability on standard BZO panels | Relationship to temazepam |
|---|---|---|
| Temazepam | Generally detected reliably at standard cutoffs | Target compound; also a minor diazepam metabolite |
| Diazepam | Generally detected reliably | Parent compound; metabolizes in part to temazepam and oxazepam |
| Oxazepam | Generally detected reliably | Shares the same metabolic family and core antibody target |
| Chlordiazepoxide | Generally detected reliably | Same metabolic family |
| Lorazepam | Detection can be less consistent at standard cutoffs | Different conjugation pathway, lower cross reactivity on some assays |
| Clonazepam | Detection can be less consistent at standard cutoffs | Structurally distinct; some assays need a lower cutoff or a dedicated antibody |
| Alprazolam | Detection can be less consistent at standard cutoffs | Structurally distinct triazolo ring system |
This pattern is one reason laboratories and treatment programs that specifically need to monitor lorazepam, clonazepam, or alprazolam compliance sometimes request a lower cutoff or a drug specific confirmation test rather than relying only on the general BZO screen. Temazepam does not usually require that extra step because it falls inside the detectability range the standard panel was built around, but any single cup or card's actual cross reactivity profile should be confirmed with the manufacturer's package insert for that specific product.
The Medical Review Officer Step
A nonnegotiable part of any employment or regulated testing program is medical review officer (MRO) review of a confirmed positive result. The MRO is a licensed physician trained to interpret laboratory results in the context of an individual's reported medications. If someone has a valid prescription for temazepam, that documentation is presented to the MRO, not argued with the collection site or the lab. The MRO decides, based on the prescription, the dose, and the confirmed laboratory finding, whether the result is reported to the employer as positive or as verified negative due to legitimate medical use. This article does not offer medical or legal advice, and any person with questions about how a specific prescription interacts with a specific testing program should raise it directly with the MRO assigned to that program.
Programs that want a dependable first line screen for benzodiazepines, including temazepam, typically rely on multi panel drug test cups that include a BZO strip alongside the other panels a program requires. For a closer look at how the BZO panel performs across the wider benzodiazepine class, including detection windows and cutoff considerations, see the related post on the benzodiazepine drug test BZO panel. Because temazepam shares part of its metabolic pathway with diazepam, the post on whether diazepam shows up on a drug test is also useful background for interpreting a mixed or ambiguous benzodiazepine result.
What a Positive Result Does Not Tell You
A positive BZO screen tells a collector or an employer that a benzodiazepine class compound is present above the cutoff. It does not identify the specific drug, the dose taken, or whether the use was medically supervised. Only confirmation testing identifies the specific compound, and only the MRO process connects that finding to a legitimate medical explanation when one exists. Treating a screening positive as a final verdict, without confirmation and without giving the tested individual a chance to produce prescription documentation to the MRO, skips steps that every credible testing program is built around.
Frequently asked questions
Does temazepam show up on a standard benzodiazepine drug test?
Yes. Temazepam shares enough chemical similarity with the diazepam and oxazepam metabolic family that it is generally detected reliably by standard BZO immunoassay panels at typical cutoff concentrations.
Will temazepam be confused with another benzodiazepine on the screen?
The screening immunoassay only reports that a benzodiazepine class compound is present. It cannot by itself distinguish temazepam from diazepam, oxazepam, or another benzodiazepine that shares the same antibody target. Laboratory confirmation by GC/MS or LC/MS identifies the specific compound.
Can a prescription for temazepam cause someone to fail a drug test?
A prescription does not prevent a positive screening result, because the immunoassay reacts to the drug itself, not to whether it was prescribed. The prescription is presented to the medical review officer, who determines how the confirmed result is reported based on that documentation.
Why do some benzodiazepines show up more reliably than others?
Standard BZO immunoassays were built around antibodies that react strongly to the diazepam and oxazepam metabolic family, which includes temazepam. Benzodiazepines with different chemical structures or metabolite conjugation, such as lorazepam and clonazepam, can show reduced cross reactivity on some panels at standard cutoffs.
Does a negative BZO screen rule out temazepam use?
No. A concentration below the panel's cutoff, a very recent dose, or an assay with lower sensitivity to a particular benzodiazepine can all produce a negative screen even when the drug was used. Programs that need certainty for a specific compound typically request targeted laboratory confirmation.
What should someone do if they are prescribed temazepam and facing a workplace test?
Bring the prescription information to the collection process and be prepared to discuss it with the medical review officer if contacted. This is a documentation and verification step handled by the MRO, not a decision made at the collection site.
This article is general information about drug testing science and procedure. It is not medical or legal advice. Anyone with questions about a specific prescription, test result, or testing program should consult a qualified medical review officer or legal counsel.
